Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum‐endemic sub‐Saharan Africa
Open Access
- 4 June 2003
- journal article
- review article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 8 (6) , 488-506
Abstract
Summary: Plasmodium falciparum malaria in pregnancy poses substantial risk to a pregnant woman and her neonate through anaemia and low birth weight (LBW), respectively, and is responsible for up to 35% of preventable LBW in malaria‐endemic areas. Chemoprophylaxis or intermittent preventive treatment (IPT) with an effective antimalarial can ameliorate the adverse effects of malaria during pregnancy. Current guidelines from the WHO recommend that women in highly malarious areas receive IPT with an effective antimalarial. Two central considerations in evaluating drugs for use during pregnancy are safety for the mother and her foetus and effectiveness, which is determined by efficacy, cost, availability, deliverability and acceptability of the drug. These factors may be scored and potential drugs or drug combinations ranked in order of potential effectiveness for use in prevention programmes. The seven most promising regimens are all IPT, primarily because they are more easily delivered and less expensive than chemoprophylaxis. Currently, IPT with sulphadoxine–pyrimethamine (SP) is more likely to have the best overall effectiveness in preventing adverse outcomes associated with malaria in pregnancy. Its low cost, wide availability, easy deliverability and acceptability make it the clear choice in countries where efficacy of the drug remains good. For countries where resistance to SP is rising or already high, amodiaquine (alone or in combination with SP or artesunate) artesunate + SP, chlorproguanil–dapsone (with and without artesunate) and artemether–lumefantrine require urgent evaluation for use in pregnancy.Keywords
This publication has 123 references indexed in Scilit:
- Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancyTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997–1999Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- Severe falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- Treatment of Sexually Transmitted Bacterial Diseases in Pregnant WomenDrugs, 2000
- The Safety of Antimalarial Drugs in PregnancyDrug Safety, 1996
- Mefloquine pharmacokinetics in pregnant women with acute falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- The distribution of birth weights in Gambian women who received malaria chemoprophylaxis during their first pregnancy and in control womenTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Amodiaquine-induced fulminant hepatitisJournal of Hepatology, 1988
- Dapsone is safe during pregnancyJournal of the American Academy of Dermatology, 1985
- The Contribution of Low Birth Weight to Infant Mortality and Childhood MorbidityNew England Journal of Medicine, 1985